Skip to content
The Nexus
DossierENTITY

patent cliff

Coverage of patent cliff in the Nexus archive.

Earliest in view: Aug 3 · 16:24 UTCMost recent: Aug 3 · 16:24 UTC
Co-mentioned in this coverage
AstraZenecaorganization1Bristol Myers Squibborganization1antitrust riskstopic1investorstopic1shareholderstopic1
Recent coverage
  • BUSINESSAug 3 · 16:24 UTCFINANCIAL TIMES WORLD
    AstraZeneca investors raise concerns over mega-merger talks

    AstraZeneca investors are expressing concerns about a potential $400 billion merger with Bristol Myers Squibb, citing risks related to an impending patent cliff and antitrust challenges.

patent cliff · Dossier · The Nexus